PUBLICATIONS

Pharmacokinetic distinctions between small molecules and biologics in treating rheumatoid arthritis: implications for personalized therapeutic strategies and formulation development

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author & Corresponding author

J. Pharm. Investig., In-press (2025).

Emerging roles of heme oxygenase 2 (HO-2) in cancer: Implications for diagnosis and therapy

Sonny C. Ramos, Seung-Hyun Jeong*, Yong-An Lee, Jong-Jin Kim

*First-author

Biochim. Biophys. Acta Mol. Basis Dis., 1872, 168057 (2026). https://doi.org/10.1016/j.bbadis.2025.168057

Interpretation of the Transcriptome-Based Signature of Tumor-Initiating Cells, the Core of Cancer Development, and the Construction of a Machine Learning-Based Classifier

Seung-Hyun Jeong*, Jong-Jin Kim, Ji-Hun Jang, Young-Tae Chang

*First-author & Corresponding author

Cells, 14(16), 1255 (2025). https://doi.org/10.3390/cells14161255

Unraveling the impact of renal impairment and renal replacement therapy modalities on fluconazole pharmacokinetics

Ji-Hun Jang, Ju-Hwan Jeong, Seung-Hyun Jeong*

*Corresponding author

Eur. J. Clin. Pharmacol., In-press (2025). https://doi.org/10.1007/s00228-025-03901-y

Necessity of considering sex factors in the clinical application of transdermal formulations

Seung-Hyun Jeong*, Se-Jin Ko, Hyeon-Hee Eom, Eon-Ji Han, Ji-Hun Jang, Yong-Bok Lee

*First-author & Corresponding author

J. Pharm. Investig., In-press (2025). https://doi.org/10.1007/s40005-025-00761-7

Precision pharmacokinetics of quetiapine: A physiologically-based model incorporating liver cirrhosis and CYP3A4 polymorphisms

Seung-Min Lee, Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

J. Clin. Pharmacol., In-press (2025). https://doi.org/10.1002/jcph.70079

Structure-based analysis of heme oxygenase subtype-selective inhibition activity of tumor-initiating cell near-infrared probe: a promising therapeutic agent for metastatic lung cancer

Chi-Ho Lee, Seul-Ki Mun, Ji-Hun Jang, Hyun-Bo Sim, Se-Na Kim, Yong-An Lee, Jong-Jin Kim, Seung-Hyun Jeong*

*Corresponding author

Int. J. Biol. Macromol., 318, 144863 (2025). https://doi.org/10.1016/j.ijbiomac.2025.144863

Population modeling of pharmacokinetic variability of epinastine, a histamine H1 receptor antagonist, according to cytochrome P450 2D6 phenotypic polymorphisms

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

Naunyn Schmiedebergs Arch. Pharmacol., In-press (2025). https://doi.org/10.1007/s00210-025-04299-1

Exposure risk assessment of di(2-ethylhexyl)phthalate (DEHP) using human population pharmacokinetic modeling of DEHP and its major in vivo metabolites

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

Arch. Toxicol., 99, 3673-3687 (2025). https://doi.org/10.1007/s00204-025-04083-3

Current status of development of oral formulations combining omega-3 fatty acids and statin ingredients and prospects for new formulations

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

J. Pharm. Innov., 20, 53 (2025). https://doi.org/10.1007/s12247-025-09959-6

Exposure risk assessment through toxicodynamics assessment of 4-tert-octylphenol and estimation of new reference values based on human tissue toxicity

Dae-Han Park, Ji-Hun Jang, Jong-Jin Kim, Seung-Hyun Jeong*

*Corresponding author

Environ. Pollut., 372, 125969 (2025). https://doi.org/10.1016/j.envpol.2025.125969

Development of a physiologically based pharmacokinetic model for quantitative interpretation of transdermal drug delivery of rotigotine, a dopamine agonist for treating Parkinson's disease

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

Eur. J. Drug Metab. Pharmacokinet., 50, 187-204 (2025). https://doi.org/10.1007/s13318-025-00938-3

Considerations of sex in bioequivalence assessments: does sex affect pharmacokinetic variability between evaluation formulations?

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

Eur. J. Clin. Pharmacol., 81, 583-596 (2025). https://doi.org/10.1007/s00228-025-03813-x

Pharmacokinetic prediction of immediate- and extended-release tablets for patients with liver disease using whole body physiologically-based pharmacokinetic modeling for the antipsychotic drug quetiapine

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

AAPS PharmSciTech., 26, 8 (2025). https://doi.org/10.1208/s12249-024-02995-4

Population pharmacokinetic modeling study and discovery of covariates for the antidepressant sertraline, a serotonin selective reuptake inhibitor

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

Comput. Biol. Med., 183, 109319 (2024). https://doi.org/10.1016/j.compbiomed.2024.109319

Population Pharmacokinetics of Loxoprofen and its alcoholic metabolites in healthy Korean men

Ji-Hun Jang, Ho-Suk Kang, Seung-Hyun Jeong*

*Corresponding author

DARU J. Pharm. Sci., 32, 631-648 (2024). https://doi.org/10.1007/s40199-024-00533-y

Human risk assessment through development and application of a physiologically based toxicokinetic model for 4-tert-octylphenol

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

Environ. Pollut., 360, 124613 (2024). https://doi.org/10.1016/j.envpol.2024.124613

Structure-Based Analysis of Cefaclor Pharmacokinetic Diversity According to Human Peptide Transporter-1 Genetic Polymorphism

Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

Int. J. Mol. Sci., 25(13), 6880 (2024). https://doi.org/10.3390/ijms25136880

Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach

Seung-Min Lee, Ji-Hun Jang, Seung-Hyun Jeong*

*Corresponding author

Naunyn Schmiedebergs Arch. Pharmacol., 397, 8311-8347 (2024). https://doi.org/10.1007/s00210-024-03190-9

Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis

Ji-Hun Jang, Ju-Hwan Jeong, Seung-Hyun Jeong*

*Corresponding author

Naunyn Schmiedebergs Arch. Pharmacol., 397, 8285-8309 (2024). https://doi.org/10.1007/s00210-024-03185-6

Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation

Hyun Bo Sim, Jun Sang Son, Sunil K. Gupta, Seung-Hyun Jeong*, Yu-Jeong Choi, Ji Yeon Han, Sonny C. Ramos, Hyeongyeong Kim, Dae-Han Park, Ho Jin Yoo, Young Joo Yoo, Dong-Jo Chang, Seul-Ki Mun, Young Ho Seo, Jong-Jin Kim

*Co-author

Int. Immunopharmacol., 137, 112470 (2024). https://doi.org/10.1016/j.intimp.2024.112470

Pharmacokinetic Analysis of Levodropropizine and Its Potential Therapeutic Advantages Considering Eosinophil Levels and Clinical Indications

Ji-Hun Jang, Young-Jin Cho, Seung-Hyun Jeong*

*Corresponding author

Pharmaceuticals, 17(2), 234 (2024). https://doi.org/10.3390/ph17020234

Is Gender an Important Factor in the Precision Medicine Approach to Levocetirizine?

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Pharmaceutics, 16(1), 146 (2024). https://doi.org/10.3390/pharmaceutics16010146

Sex differences in 4-tert-octylphenol toxicokinetics: Exploration of sex as an effective covariate through an in vivo modeling approach

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Toxicology, 502, 153733 (2024). https://doi.org/10.1016/j.tox.2024.153733

Population pharmacokinetic modeling of levodropropizine: Extended application to comparative analysis between commercial formulations and exploration of pharmacokinetic effects of diet

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Naunyn Schmiedebergs Arch. Pharmacol., 397, 4403-4418 (2024). https://doi.org/10.1007/s00210-023-02889-5

Modeling population pharmacokinetics of morniflumate in healthy Korean men: extending pharmacometrics analysis to niflumic acid, its major active metabolite

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Naunyn Schmiedebergs Arch. Pharmacol., 397, 843-856 (2024). https://doi.org/10.1007/s00210-023-02640-0

Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Biomedicines, 11(11), 3021 (2023). https://doi.org/10.3390/ biomedicines11113021

A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function

Ji-Hun Jang, Seung-Hyun Jeong*, Yong-Bok Lee

*First-author

J. Pharm. Investig., 53, 857-868 (2023). https://doi.org/10.1007/s40005-023-00638-7

P-glycoprotein mechanical functional analysis using in silico molecular modeling: Pharmacokinetic variability according to ABCB1 c.2677G > T/A genetic polymorphisms

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Int. J. Biol. Macromol., 249, 126777 (2023). https://doi.org/10.1016/j.ijbiomac.2023.126777

Inter-individual exposure variability interpretation through reflection of biological age algorithm in physiologically based toxicokinetic model: Application to human risk assessment of di-isobutyl-phthalate

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Environ. Pollut., 336, 122388 (2023). https://doi.org/10.1016/j.envpol.2023.122388

Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics

Ji-Hun Jang, Seung-Hyun Jeong*, Yong-Bok Lee

*First-author

J. Pharm. Anal., 13(6), 660-672 (2023). https://doi.org/10.1016/j.jpha.2023.04.001

Establishment of a fexofenadine population pharmacokinetic (PK)–pharmacodynamic (PD) model and exploration of dosing regimens through simulation

Ji-Hun Jang, Seung-Hyun Jeong*, Yong-Bok Lee

*First-author

J. Pharm. Investig., 53, 427-441 (2023). https://doi.org/10.1007/s40005-023-00615-0

Population Pharmacokinetic Modeling of Zaltoprofen in Healthy Adults: Exploring the Dosage Regimen

Ji-Hun Jang, Seung-Hyun Jeong*, Yong-Bok Lee

*First-author

Pharmaceuticals, 16(2), 161 (2023). https://doi.org/10.3390/ph16020161

Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model

Ji-Hun Jang, Seung-Hyun Jeong*, Yong-Bok Lee

*First-author

Pharmacotherapy, 43, 145-157 (2023). https://doi.org/10.1002/phar.2762

Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

J. Pharm. Investig., 53, 119-152 (2023). https://doi.org/10.1007/s40005-022-00589-5

Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Pharmaceutics, 14(12), 2720 (2022). https://doi.org/10.3390/pharmaceutics14122720

Physiologically based pharmacokinetic (PBPK) modeling of lornoxicam: Exploration of doses for CYP2C9 genotypes and patients with cirrhosis

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

J. Pharm. Sci., 111(11), 3174-3184 (2022). https://doi.org/10.1016/j.xphs.2022.08.035

Development of physiologically-based toxicokinetic-toxicodynamic (PBTK-TD) model for 4-nonylphenol (4-NP) reflecting physiological changes according to age in males: Application as a new risk assessment tool with a focus on toxicodynamics

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Environ. Pollut., 312, 120041 (2022). https://doi.org/10.1016/j.envpol.2022.120041

Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically-based pharmacokinetic (PBPK) modeling: Analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Arch. Toxicol., 96(10), 2687-2715 (2022). https://doi.org/10.1007/s00204-022-03328-9

Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Pharmaceutics, 14(4), 771 (2022). https://doi.org/10.3390/pharmaceutics14040771

Population pharmacokinetic analysis of lornoxicam in healthy Korean males considering creatinine clearance and CYP2C9 genetic polymorphism

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

J. Pharm. Investig., 52(1), 109-127 (2022). https://doi.org/10.1007/s40005-021-00550-y

Toxicokinetic studies of di-isobutyl phthalate focusing on the exploration of gender differences in rats

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Chemosphere, 286(Part1), 131706 (2022). https://doi.org/10.1016/j.chemosphere.2021.131706

Toxicokinetics of di-isodecyl phthalate and its major metabolites in rats through the application of a developed and validated UHPLC-ESI-MS/MS method

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Arch. Toxicol., 95(11), 3515-3537 (2021). https://doi.org/10.1007/s00204-021-03153-6

Oral and Lymphatic Delivery of Paclitaxel via Lipid Nanocapsules

Phuong Tran, Ji-Hun Jang, Seung-Hyun Jeong*, Yong-Bok Lee

*Co-author

Yakhak Hoeji, 65(5), 375-385 (2021). https://doi.org/10.17480/psk.2021.65.5.375

Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Pharmaceutics, 13(7), 1050 (2021). https://doi.org/10.3390/pharmaceutics13071050

Oral delivery of topotecan in polymeric nanoparticles: Lymphatic distribution and pharmacokinetics

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

J. Control. Release, 335, 86-102 (2021). https://doi.org/10.1016/j.jconrel.2021.05.017

Human risk assessment of di-isobutyl phthalate through the application of a developed physiologically based pharmacokinetic model of di-isobutyl phthalate and its major metabolite mono-isobutyl phthalate

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Arch. Toxicol., 95(7), 2385-2402 (2021). https://doi.org/10.1007/s00204-021-03057-5

Simultaneous determination of fourteen components of Gumiganghwal-tang tablet in human plasma by UPLC-ESI-MS/MS and its application to pharmacokinetic study

Seung-Hyun Jeong*, Ji-Hun Jang, Guk-Yeo Lee, Seung-Jung Yang, Hea-Young Cho, Yong-Bok Lee

*First-author

J. Pharm. Anal., 11(4), 444-457 (2021). https://doi.org/10.1016/j.jpha.2020.08.003

Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

J. Pharm. Anal., 11(3), 351-363 (2021). https://doi.org/10.1016/j.jpha.2020.07.001

Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Pharmaceutics, 13(5), 754 (2021). https://doi.org/10.3390/pharmaceutics13050754

Pharmacokinetic Changes According to Single or Multiple Oral Administrations of Socheongryong-Tang to Rats: Presented as a Typical Example of Changes in the Pharmacokinetics Following Multiple Exposures to Herbal Medicines

Seung-Hyun Jeong*, Ji-Hun Jang, Da-Hwa Jung, Guk-Yeo Lee, Yong-Bok Lee

*First-author

Pharmaceutics, 13(4), 478 (2021). https://doi.org/10.3390/pharmaceutics13040478

Simultaneous determination of asarinin, β-eudesmol, and wogonin in rats using ultraperformance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic studies following administration of standards and Gumiganghwal-tang

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Biomed. Chromatogr., 35(4), e5021 (2021). https://doi.org/10.1002/bmc.5021

In vivo and in vitro studies of Banhahoobak-tang tablets using UPLC-ESI-MS/MS with polarity switching

Seung-Hyun Jeong*, Ji-Hun Jang, Guk-Yeo Lee, Seung-Jung Yang, Hea-Young Cho, Yong-Bok Lee

*First-author

J. Pharm. Biomed. Anal., 196, 113911 (2021). https://doi.org/10.1016/j.jpba.2021.113931

Simultaneous determination of three iridoid glycosides of Rehmannia glutinosa in rat biological samples using a validated hydrophilic interaction-UHPLC-MS/MS method in pharmacokinetic and in vitro studies

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

J. Sep. Sci., 43(22), 4148-4161 (2020). https://doi.org/10.1002/jssc.202000809

Enhanced lymphatic delivery of methotrexate using W/O/W nanoemulsion: In vitro characterization and pharmacokinetic study

Ji-Hun Jang, Seung-Hyun Jeong*, Yong-Bok Lee

*Co-author

Pharmaceutics, 12(10), 978 (2020). https://doi.org/10.3390/pharmaceutics12100978

Toxicokinetics of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rats: UPLC-ESI-MS/MS method development for the simultaneous determination of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rat plasma, urine, feces, and 11 various tissues collected from a toxicokinetic study

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Food Chem. Toxicol., 145, 111747 (2020). https://doi.org/10.1016/j.fct.2020.111747

Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Pharmaceuticals, 13(9), 231 (2020). https://doi.org/10.3390/ph13090231

Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic studies

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Biomed. Chromatogr., 34(9), e4848 (2020). https://doi.org/10.1002/bmc.4848

Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Arch. Toxicol., 94(7), 2377-2400 (2020). https://doi.org/10.1007/s00204-020-02748-9

Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Pharmaceutics, 12(4), 374 (2020). https://doi.org/10.3390/pharmaceutics12040374

A sensitive UPLC–ESI–MS/MS method for the quantification of cinnamic acid in vivo and in vitro: application to pharmacokinetic and protein binding study in human plasma

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, In-Joon Oh, Yong-Bok Lee

*First-author

J. Pharm. Investig., 50(2), 159-172 (2020). https://doi.org/10.1007/s40005-019-00444-0

Pharmacokinetic Comparison of Epinastine Using Developed Human Plasma Assays

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Molecules, 25(1), 209 (2020). https://doi.org/10.3390/molecules25010209

Gender differences in pharmacokinetics and tissue distribution of 4-n-nonylphenol in rats

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Arch. Toxicol., 93(11), 3121-3139 (2019). https://doi.org/10.1007/s00204-019-02581-9

Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans

Ji-Hun Jang, Seung-Hyun Jeong*, Hea-Young Cho, Yong-Bok Lee

*First-author

Pharmaceutics, 11(10), 531 (2019). https://doi.org/10.3390/pharmaceutics11100531

Simultaneous determination of fourteen main active components in Gumiganghwal-tang tablet by using a newly developed UPLC-ESI-MS/MS method

Seung-Hyun Jeong*, Ji-Hun Jang, Guk-Yeo Lee, Seung-Jung Yang, Hea-Young Cho, Yong-Bok Lee

*First-author

J. Chromatogr. B, 1126-1127, 121743 (2019). https://doi.org/10.1016/j.jchromb.2019.121743

A novel and sensitive UPLC–MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies

Seung-Hyun Jeong*, Ji-Hun Jang, Yong-Bok Lee

*First-author

Biomed. Chromatogr., 33(10), e4627 (2019). https://doi.org/10.1002/bmc.4627

Simultaneous determination of diethyl phthalate and its major metabolite, monoethyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study by ultrahigh performance liquid chromatography-tandem mass spectrometry

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

J. Pharm. Biomed. Anal., 173, 108-119 (2019). https://doi.org/10.1016/j.jpba.2019.05.027

Preparation and in vitro/in vivo characterization of polymeric nanoparticles containing methotrexate to improve lymphatic delivery

Ji-Hun Jang, Seung-Hyun Jeong*, Yong-Bok Lee

*Co-author

Int. J. Mol. Sci., 20(13), 3312 (2019). https://doi.org/10.3390/ijms20133312

Comparison of UPLC-MS/MS and HPLC-UV methods for the determination of zaltoprofen in human plasma

Ji-Hun Jang, Seung-Hyun Jeong*, Hea-Young Cho, Yong-Bok Lee

*First-author

J. Pharm. Investig., 49(6), 613-624 (2019). https://doi.org/10.1007/s40005-018-00416-w

Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study

Seung-Hyun Jeong*, Ji-Hun Jang, Seong-Ho Ham, Seung-Jung Yang, Hea-Young Cho, Yong-Bok Lee

*First-author

J. Chromatogr. B, 1095, 214-225 (2018). https://doi.org/10.1016/j.jchromb.2018.07.043

Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery

Seung-Hyun Jeong*, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee

*First-author

Arch. Pharm. Res., 41(8), 797-814 (2018). https://doi.org/10.1007/s12272-018-1060-0

Page updated

Google Sites

Report abuse

PUBLICATIONS

Pharmacokinetic distinctions between small molecules and biologics in treating rheumatoid arthritis: implications for personalized therapeutic strategies and formulation development

Emerging roles of heme oxygenase 2 (HO-2) in cancer: Implications for diagnosis and therapy

Interpretation of the Transcriptome-Based Signature of Tumor-Initiating Cells, the Core of Cancer Development, and the Construction of a Machine Learning-Based Classifier

Unraveling the impact of renal impairment and renal replacement therapy modalities on fluconazole pharmacokinetics

Necessity of considering sex factors in the clinical application of transdermal formulations

Precision pharmacokinetics of quetiapine: A physiologically-based model incorporating liver cirrhosis and CYP3A4 polymorphisms

Structure-based analysis of heme oxygenase subtype-selective inhibition activity of tumor-initiating cell near-infrared probe: a promising therapeutic agent for metastatic lung cancer

Population modeling of pharmacokinetic variability of epinastine, a histamine H1 receptor antagonist, according to cytochrome P450 2D6 phenotypic polymorphisms

Exposure risk assessment of di(2-ethylhexyl)phthalate (DEHP) using human population pharmacokinetic modeling of DEHP and its major in vivo metabolites

Current status of development of oral formulations combining omega-3 fatty acids and statin ingredients and prospects for new formulations

Exposure risk assessment through toxicodynamics assessment of 4-tert-octylphenol and estimation of new reference values ​​based on human tissue toxicity

Development of a physiologically based pharmacokinetic model for quantitative interpretation of transdermal drug delivery of rotigotine, a dopamine agonist for treating Parkinson's disease

Considerations of sex in bioequivalence assessments: does sex affect pharmacokinetic variability between evaluation formulations?

Pharmacokinetic prediction of immediate- and extended-release tablets for patients with liver disease using whole body physiologically-based pharmacokinetic modeling for the antipsychotic drug quetiapine

Population pharmacokinetic modeling study and discovery of covariates for the antidepressant sertraline, a serotonin selective reuptake inhibitor

Population Pharmacokinetics of Loxoprofen and its alcoholic metabolites in healthy Korean men

Human risk assessment through development and application of a physiologically based toxicokinetic model for 4-tert-octylphenol

Structure-Based Analysis of Cefaclor Pharmacokinetic Diversity According to Human Peptide Transporter-1 Genetic Polymorphism

Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach

Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis

Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation

Pharmacokinetic Analysis of Levodropropizine and Its Potential Therapeutic Advantages Considering Eosinophil Levels and Clinical Indications

Is Gender an Important Factor in the Precision Medicine Approach to Levocetirizine?

Sex differences in 4-tert-octylphenol toxicokinetics: Exploration of sex as an effective covariate through an in vivo modeling approach

Population pharmacokinetic modeling of levodropropizine: Extended application to comparative analysis between commercial formulations and exploration of pharmacokinetic effects of diet

Modeling population pharmacokinetics of morniflumate in healthy Korean men: extending pharmacometrics analysis to niflumic acid, its major active metabolite

Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling

A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function

P-glycoprotein mechanical functional analysis using in silico molecular modeling: Pharmacokinetic variability according to ABCB1 c.2677G > T/A genetic polymorphisms

Inter-individual exposure variability interpretation through reflection of biological age algorithm in physiologically based toxicokinetic model: Application to human risk assessment of di-isobutyl-phthalate

Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics

Establishment of a fexofenadine population pharmacokinetic (PK)–pharmacodynamic (PD) model and exploration of dosing regimens through simulation

Population Pharmacokinetic Modeling of Zaltoprofen in Healthy Adults: Exploring the Dosage Regimen

Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model

Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors

Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling

Physiologically based pharmacokinetic (PBPK) modeling of lornoxicam: Exploration of doses for CYP2C9 genotypes and patients with cirrhosis

Development of physiologically-based toxicokinetic-toxicodynamic (PBTK-TD) model for 4-nonylphenol (4-NP) reflecting physiological changes according to age in males: Application as a new risk assessment tool with a focus on toxicodynamics

Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically-based pharmacokinetic (PBPK) modeling: Analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population

Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms

Population pharmacokinetic analysis of lornoxicam in healthy Korean males considering creatinine clearance and CYP2C9 genetic polymorphism

Toxicokinetic studies of di-isobutyl phthalate focusing on the exploration of gender differences in rats

Toxicokinetics of di-isodecyl phthalate and its major metabolites in rats through the application of a developed and validated UHPLC-ESI-MS/MS method

Oral and Lymphatic Delivery of Paclitaxel via Lipid Nanocapsules

Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach

Oral delivery of topotecan in polymeric nanoparticles: Lymphatic distribution and pharmacokinetics

Human risk assessment of di-isobutyl phthalate through the application of a developed physiologically based pharmacokinetic model of di-isobutyl phthalate and its major metabolite mono-isobutyl phthalate

Simultaneous determination of fourteen components of Gumiganghwal-tang tablet in human plasma by UPLC-ESI-MS/MS and its application to pharmacokinetic study

Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma

Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects

Pharmacokinetic Changes According to Single or Multiple Oral Administrations of Socheongryong-Tang to Rats: Presented as a Typical Example of Changes in the Pharmacokinetics Following Multiple Exposures to Herbal Medicines

Simultaneous determination of asarinin, β-eudesmol, and wogonin in rats using ultraperformance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic studies following administration of standards and Gumiganghwal-tang

In vivo and in vitro studies of Banhahoobak-tang tablets using UPLC-ESI-MS/MS with polarity switching

Simultaneous determination of three iridoid glycosides of Rehmannia glutinosa in rat biological samples using a validated hydrophilic interaction-UHPLC-MS/MS method in pharmacokinetic and in vitro studies

Enhanced lymphatic delivery of methotrexate using W/O/W nanoemulsion: In vitro characterization and pharmacokinetic study

Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats

Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic studies

Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate

Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects

A sensitive UPLC–ESI–MS/MS method for the quantification of cinnamic acid in vivo and in vitro: application to pharmacokinetic and protein binding study in human plasma

Pharmacokinetic Comparison of Epinastine Using Developed Human Plasma Assays

Gender differences in pharmacokinetics and tissue distribution of 4-n-nonylphenol in rats

Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans

Simultaneous determination of fourteen main active components in Gumiganghwal-tang tablet by using a newly developed UPLC-ESI-MS/MS method

A novel and sensitive UPLC–MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies

Simultaneous determination of diethyl phthalate and its major metabolite, monoethyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study by ultrahigh performance liquid chromatography-tandem mass spectrometry

Preparation and in vitro/in vivo characterization of polymeric nanoparticles containing methotrexate to improve lymphatic delivery

Comparison of UPLC-MS/MS and HPLC-UV methods for the determination of zaltoprofen in human plasma

Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study

Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery

Exposure risk assessment through toxicodynamics assessment of 4-tert-octylphenol and estimation of new reference values based on human tissue toxicity

P-glycoprotein mechanical functional analysis using in silico molecular modeling: Pharmacokinetic variability according to ABCB1 c.2677G > T/A genetic polymorphisms